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This Research Topic aims to cover recent progress in research
studying how genetic make-up and environmental factors can
contribute to the development of mental disorders such as
anxiety, depression, schizophrenia, and psychoactive substances
abuse. It has brought together leading experts in the field to
address these questions from different angles in eleven reviews,
seven original research articles and two theoretic/opinion papers.
The first three articles describe several techniques which are
valuable tools to study the role of neurotransmitters such as sero-
tonin (5-HT) in the pathophysiology and the treatment of psychi-
atric disorders. First, Prof. Gardier (2013) nicely summarizes the
main advantages as well as some limitations of using microdialy-
sis in wildtype (WT) and knockout (KO) mice. His team showed
that paroxetine-induced increased in cortical 5-HT extracellu-
lar level was enhanced in 5-HT1A receptor KO mice compared
to WT animals. Then, by performing loose-seal cell-attached
electrophysiological recordings in 5-HT transporter knockout
(Sert−/−) and tryptophan hydroxylase-2 knockout (Tph2−/−)
mice, Araragi et al. (2013) demonstrate that the sensitivity of
somatodendritic 5-HT1A receptors does not predict the mag-
nitude of 5-HT neuron auto-inhibition. Finally, Mendez-David
et al.’s (2013) results suggest that isolation of peripheral blood
mononuclear cells (PBMCs) from mice by submandibular bleed-
ing is a useful technique to screen putative biomarkers relevant to
the pathophysiology of mood disorders such as β-arrestin 1. They
found that the reduced β-arrestin 1 levels found in PBMCs from
anxious/depressed mice was restored to normal levels following
chronic treatment with fluoxetine.
The following eleven articles provide excellent insights into
the interaction between gene and environment in mental dis-
orders as well as the role of several transmitters/neuropeptides
and the different therapeutic strategies. El-Hage et al. (2013) ele-
gantly expose the potential predictors of response/non-response
to antidepressants and discuss their clinical and practical implica-
tions. Alongside with reviewing several markers that can be used
to predict response to pharmacotherapy, they also describe fac-
tors that might affect the expression of these markers, including
environmental or genetic factors and comorbidities. Then, focus-
ing mainly on the impact of polymorphisms on anxiety-like and
depression-like behavior in rodents, Armario and Nadal (2013)
discuss how individual differences can contribute to explain
differential susceptibility to develop behavioral alterations. They
also emphasize methodological problems that can lead to inap-
propriate or over-simplistic interpretations. Olivier et al. (2013)
review the role of the GABAA receptor and the serotonergic
system in drug discovery for anxiety disorders. They elegantly
highlight how genetic studies aiming to unravel the neurobi-
ology of anxiety have proven to be challenging, and describe
how the development of animal models (including genetically
modified rodents) has helped to clarify the complex interplay
between genes and environment in anxiety-like behaviors. In his
opinion article, Dr. Pinna (2014) illustrates the therapeutic strate-
gies to increase neurosteroidogenesis and improve posttraumatic
stress disorder by enhancing GABAergic neurotransmission. He
also discusses the several therapeutic advantages of targeting
allopregnanolone biosynthesis with selective neurosteroidogenic
agents. Browne and Lucki (2013) examine the preclinical lit-
erature on the antidepressant-like effects of ketamine. After
extensively reviewing animal studies which suggest that acute
ketamine produces antidepressant-like effect on many behavioral
tests, they discuss the potential molecular mechanisms involved.
Focusing on direct evidence in the human post-mortem brain
as well as rodent genetic and pharmacological studies, Lin and
Sibille (2013) summarize the current literature on deficits in
somatostatin in neuropsychiatric and neurodegenerative disor-
ders. They conclude that clarifying the role of somatostatin and
its regulation of GABA inhibition could provide new therapeu-
tic strategies. Smith et al. (2014) review recent preclinical data
on relaxin-3 a newly discovered neuropeptide that binds, and
activates the G-protein coupled receptor, RXFP3. They comment
on data which suggests that endogenous relaxin-3/RXFP3 sig-
naling promotes arousal and contributes to the central response
to stress. This could be relevant and/or potentially translatable
to the etiology and treatment of major depression and anxiety.
Schirmbeck and Zink (2013) review the contributions of phar-
macological and genetic factors in schizophrenia patients with
comorbid obsessive-compulsive symptoms (OCS). In this arti-
cle, they present an in-depth and very detailed coverage of the
concepts explaining the co-occurrence of OCS in schizophre-
nia. They highlight that the effects of environmental factors on
onset or symptom has been scarcely investigated and suggest
that besides pharmacological treatment as a relevant factor, fur-
ther environmental factors and gene polymorphisms could play
an important role in the development of OCS in schizophrenia.
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Sumiyoshi’s (2013) article aims to provide theoretical issues on
atypical antipsychotic drugs in relation to efficacy for treating
psychotic symptoms and cognition, as well as safety and tolerabil-
ity. Based on the fact that no treatments have yet been approved
for treating cognitive or negative symptoms in schizophrenia, the
author presents a hypothesis for future directions of therapeutics.
In that regard, Adams et al. (2013) report that rats with 5,7-
DHT-lesions targeting the dorsal hippocampus show potentiated
locomotor hyperactivity following treatment with phencyclidine.
Given the prominent role of the dorsal hippocampus in spa-
tial information processing, these findings have implications for
studies utilizing NMDA receptor antagonists in modeling glu-
tamatergic dysfunction in schizophrenia. Finally, using the tail
suspension test, Mitchell et al. (2013) show for the first time that
it is possible to detect antidepressant-like activity of drugs in mice
as young as P21. Their results suggest that juvenile mice (P21) are
less responsive to the antidepressant-like effects of escitalopram
than adolescent (P28).
The last five articles cover neuroscience research on drug of
abuse. In order to better understand the processes by which
peer influences take effect in prairie voles, Anacker and Ryabinin
(2013) measure alcohol intake during periods of isolation,
pair housing of high and low drinkers, and subsequent iso-
lation. By using a new method (“lickometer” apparatus) and
cross-correlation analyses, they managed to differentiate sub-
populations of high drinkers that were and were not responsive
to social influence to decrease ethanol intake. In another study,
Al-Hasani et al. (2013) investigate the interactions between var-
ious types of stress paradigms and how they influence kappa
opioid receptor (KOR)-dependent reinstatement of cocaine and
nicotine preference. They report that chronic mild stress prior to
reinstatement prevents a KOR-induced reinstatement response,
while acute exposure to stress induces potentiation of KOR-
reinstatement. These findings identify KOR as a potentially novel
therapeutic target system in drug relapse, anxiety, and depres-
sion. Assessing hypothalamic-pituitary-adrenal (HPA) axis activ-
ity during withdrawal from chronic ethanol, Pang et al. (2013)
found that mice undergoing 2 weeks of alcohol abstinence had
significantly greater corticosterone and ACTH levels following a
DEX-CRH challenge compared to water controls. Interestingly,
environmental enrichment was able to prevent the development
of abstinence-associated depression-related behaviors and correct
the pathological DEX-CRH corticosterone response. These find-
ings suggest potential for non-pharmacological interventions in
the treatment of addiction and depression. Bernheim et al. (2013)
summarize the biological factors relevant to adolescent driving
risks. The authors discuss the clinical observations in the light
of preclinical findings linking impulsivity and emotional reactiv-
ity to initiation of drug use and risks of abuse. They conclude
that rather than naive, immature and vulnerable, the adolescent
brain, particularly the prefrontal cortex, should be considered as
prewired for expecting novel experiences. Finally, highlighting the
importance of differentiating dopamine D3 from D2 receptors,
Le Foll et al. (2014) review the recent methods for measuring D3
receptor occupancy in vivo. They present novel methods using
[11C]-(+)-PHNO and PET which could provide insights into the
function of D3 receptors in addiction.
In summary, these studies illustrate how mental disorders can
arise from multiple sources. It even seems that the entire body
can impact on mental state and psychiatric health (Renoir et al.,
2013). We believe that this Frontier Research Topic will stimulate
the development of future collaborative and interdisciplinary
research.
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